Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated a greater than five-fold increase in five-

source https://finance.yahoo.com/news/bristol-myers-squibb-announces-pooled-093000966.html?.tsrc=rss